INTRODUCTION
Ventilator-associated pneumonia (VAP) is a common and life-threatening complication of mechanical ventilation. Survivors may experience respiratory insufficiency due to the fibrosis of the lung that develops during the healing process. 1 The mechanisms leading 
SUMMARY AT A GLANCE
A significant increase in human blood vascular endothelial growth factor (VEGF)-A is associated with early resolution of ventilator-associated pneumonia (VAP); this was an independent predictor of resolution despite disease severity. Experimental chronic lung infection by Pseudomonas aeruginosa in mice led to increased VEGF-A concentrations in the lung and a reciprocal decrease of proinflammatory cytokines and myeloperoxidase activity.
to resolution of VAP are incompletely understood and involve stimulation of the healing process by the alveolar macrophages. 2 Vascular endothelial growth factor (VEGF)-A belongs to the endothelium adhesion molecules that allow neutrophils to migrate between endothelial cells during inflammation. Part of its mechanism of action is also related with disruption of the endothelium and development of tissue interstitial oedema and neovascularization. 3, 4 In humans, we hypothesized that VEGF-A participates in the healing process associated with rapid resolution of VAP. In order to test this hypothesis, serial serum levels of VEGF-A were measured in patients with VAP and kinetics was associated with resolution of pneumonia. We also studied an experimental animal model of Pseudomonas aeruginosa pneumonia. VEGF-A levels were studied in relation to the other pro-inflammatory cytokines and to tissue myeloperoxidase (MPO) activity (a measure of neutrophil infiltration) in mice.
METHODS

Clinical study
A total of 200 patients with VAP and signs of the systemic inflammatory response syndrome were enrolled in a prospective, double-blind randomized placebocontrolled trial to study the efficacy of intravenous clarithromycin for treatment of VAP and sepsis. Patients were enrolled during the period June 2004-November 2005. The study protocol and written informed consent form were approved by the Ethics Committee of participating hospitals (www.clinicaltrials.gov; NCT00297674). 5 Serial blood samples were collected for seven consecutive days from patients. Samples and clinical data coming from patients allocated to the placebo arm were used. The sub-study was approved by the Ethics Committee of ATTIKON University Hospital. Inclusion criteria were: (i) written informed consent provided by first-degree relatives; (ii) patient intubation and mechanical ventilation for at least 48 h prior enrollment; (iii) age ≥ 18 years; (iv) diagnosis of VAP; and (v) signs of the systemic inflammatory response syndrome (SIRS). Patients with neutropenia, infection by the HIV and a history of oral intake of corticosteroids were excluded from the study.
VAP was diagnosed by all the following criteria: (i) new or persistent consolidation on chest X-ray; (ii) purulent tracheobronchial secretions (TBS); and (iii) a clinical pulmonary infection score (CPIS) more than 6. Patients were followed-up for 28 days. The following variables were recorded: (i) co-existing diseases; (ii) Acute Physiology and Chronic Health Evaluation (APACHE) II score and Sequential Organ Failure Assessment (SOFA) score; (iii) biochemistry, absolute blood cell counts and arterial gases; and (iv) quantitative cultures of TBS performed on baseline day 1 and on days 5 and 10.
Resolution of VAP was defined in the study protocol as resolution of all clinical signs that led to study enrolment. 5 Time to resolution of VAP was recorded.
Five millilitre of blood was sampled on day 1 and on six consecutive days after puncture of one forearm vein under aseptic conditions and collected into sterile, pyrogen-free and anticoagulant-free tubes (Vacutainer; Becton Dickinson, Cockeysville, MD, USA). Tubes were centrifuged and serum was stored immediately at −80 C until assayed. Concentrations of VEGF-A were measured using an enzyme immunosorbent assay (eBiosciences, San Diego, CA, USA); the lower detection limit was 80 pg/mL. All measurements were performed by one technician who was blind to clinical data. The same technician transferred data to the electronic data sheet in a blind fashion.
Experimental animal study
Experiments were carried out in the Laboratory for Experimental Medicine of ATTIKON University General Hospital (approval K/7570 of the Veterinary Directorate of the Prefecture of Athens) using 8-to 12-weeks-old, 25 g body weight, specific pathogen-free C57BL/6 wildtype mice (Institute Pasteur, Athens, Greece) using a published model of pneumonia. 7 After acclimatization, mice were kept at cages with constant rotation rate of 70 air-changes per hour to ensure sterility. Mice were fed standard chow (type 4rf 18) and were allowed water ad libitum. They were kept in an isolated room with a controlled temperature of 24 C and a day-night cycle of 8 am-8 pm. Mice were infected with an isolate of P. aeruginosa from the tracheobronchial secretions of a patient with VAP. The bacterial suspension was grown logarithmically overnight at 37 C in trypticase soy broth, washed, re-suspended in phosphate buffered saline (PBS) (Merck, Darmstadt, Germany) and diluted serially in PBS.
Following anaesthesia with diethyl ether (Alter Chem, Athens, Greece), mice were suspended at a 60 angle using their front incisors; a volume of 50 μL containing sham or bacterial challenge was instilled under direct visualization into the glottis and further set into the lower respiratory tract. Preliminary experiments in 15 mice showed that death started after 72 h and that 7-day mortality was 40%.
At a second stage, 41 mice were divided into three groups: sham-operation intratracheally challenged with PBS (n = 15), infection with 5 × 10 6 cfus (n = 21); and treated with colistin after intratracheal challenge with 5 × 10 6 cfus (n = 5). The last group was designed to mimic the clinical situation where treatment is administered. Colistin was selected since the pathogen was multidrug-resistant; 40 mg/kg of colistin methanesulfonate at a volume 200 μL (Norma, Ioannina, Greece) was subcutaneously administered once daily at the neck region 8 starting 24 h after bacterial challenge. Mice were sacrificed at 24, 48 and 124 h after bacterial challenge so that time readings resemble to the clinical study; mice that died before the predefined time of sacrifice were discarded. Colistintreated mice were sacrificed only at 124 h. The number of infected mice was greater than the sham group so that at least five mice would survive until 124 h. Paracetamol suppositories were administered to reduce suffering. Bronchoalveolar lavage (BAL) was sampled before sacrifice. More precisely, under ether anaesthesia the chest cavity was dissected to expose the trachea and the lungs. Then a 20-gauge cannula was gently inserted into the trachea and 1 mL of sterile PBS was infused. BAL was aspirated slowly through the cannula and stored at −80 C. Sacrifice was then performed by lethal intramuscular injection of ketamine. Midline abdominal incision was performed under aseptic conditions, intestines were displaced to the left and the lower vena cava was punctured under sterile conditions by a 20-gauge needle; 200 μL of whole blood was aspirated using one heparin-coated syringe, collected into sterile and pyrogen-free tubes (Vacutainer, Cockeysville, MD, USA) and centrifuged; plasma was stored at −80 C. Then, one specimen of the lower lobes of both lungs and of the right kidney was excised, weighted and homogenized.
Lung and kidney homogenates were serially diluted (1:10) five times; 100 μL of each dilution was plated onto MacConkey agar and incubated at 37 C for 24 h. Colonies were counted and results were expressed as the log10 value of colony-forming units per gram of tissue (cfu/g).
Albumin was measured by the bromocresol green chromogenic assay (ALB kit; Siemens, Erlangen, Germany) at the ADVIA 1800 analyzer (Siemens); the lower detection limit was 0.09 g/dL. VEGF-A, tumour Necrosis Factor alpha (TNF-α), interleukin-1β and interferongamma (IFNγ) were measured by enzyme immunosorbent assays (eBiosciences); the lower detection limits were 80, 20, 20 and 16 pg/mL, respectively. MPO activity was measured in tissues as described elsewhere 9 and results were adjusted per gram of weight.
At a third stage, 14 mice were intraperitoneally injected with 200 μL of sodium chloride 0.9% or 25 mg/kg of bevacizumab 10, 11 (Avastin, Roche, Basel, Switzerland) as pre-treatment 2 days before and after bacterial challenge; challenge was 5 × 10 6 cfus of P. aeruginosa intratracheally; mice were sacrificed 124 h after challenge.
Statistical analysis
Patients were divided into resolved and non-resolved cases of VAP. Comparisons of demographics and follow-up characteristics were performed by the Fisher exact test for qualitative variables and by the Student's t-test for quantitative variables. Serial concentrations of VEGF-A were expressed as mean AE SE and compared by the Wilcoxon's rank sum test. P values were adjusted by Bonferroni for multiple comparisons. The % change of VEGF-A from baseline was calculated and a receiver operator characteristics (ROC) curve analysis was designed to identify the best coordinate point to predict resolution of VAP. Odds ratio (OR) and 95% CI were calculated by Mantel and Haenszel statistics. OR were compared by the Breslow-Day's and by the Tarone's tests. The time to resolution of VAP was compared by the log-rank test. The % change of VEGF-A was further validated after logistic regression analysis; resolution of VAP was the dependent variable; VEGF-A change and differences of baseline demographics were the independent variables.
Mice cytokines, bacterial outgrowth and MPO activity were expressed as mean AE SE and compared by the Mann-Whitney U test.
Any value of P < 0.05 was considered statistically significant.
RESULTS
A complete serum data set for all 7 days of follow-up was available for 82 patients ( Figure S1 in Supplementary Information). Serum VEGF-A of day 1 did not correlate with APACHE II (r s = −0.086, P = 0.492) and SOFA scores (r s = +0.019, P = 0.876). Serial concentrations for patients with resolved and unresolved VAP cases are shown in Figure 1 . After adjustment for multiple comparisons, it was found that serum VEGF-A increased significantly on days 5, 6 and 7 only among resolved cases.
The first time point during follow-up where an increase of serum VEGF-A was shown was day 5. ROC curve analysis identified that more than 45% increase of VEGF-A on day 5 had the best trade-off for sensitivity and specificity associated with resolution of VAP. In total, 36 patients had less than 45% increase and 46 patients had more than 45% increase of serum VEGF-A. VAP resolved in 13 (36.1%) and in 30 (65.2%) patients, respectively (P = 0.014). As shown in Figure S2 in Supplementary Information, this positivepredictive value was constant irrespective of the depicted cut-off increase of VEGF-A; lower cut-offs, however, led to lower sensitivity. The OR for VAP resolution with more than 45% increase on day 5 was 3.32 (95% CI: 1.33-8.25). VAP also resolved earlier (Fig. 2) .
Based on baseline differences (Table S1 in Supplementary Information), forward logistic regression analysis included APACHE II score, SOFA score and 45% increase of baseline VEGF-A. We decided not to include age because APACHE II score contains information on age. Analysis confirmed findings (Table 1 ). The underlying pathogen was eradicated from quantitative TBS cultures on day 5 in 42.9% of patients with more than 45% increase of serum VEGF-A compared to 27.8% of patients with less than 45% increase (P = 0.013). These percentages were 61.1% and 42.9%, respectively, on day 10 (P = 0.130).
Sub-analysis involving the type of pathogen, showed greater resolution of VAP among patients with more than 45% increase of VEGF-A on day 5 and infection by P. aeruginosa but also among patients without documented pathogen. The OR for VAP resolution in these patients did not differ statistically from cases caused by pathogens other than P. aeruginosa (Table S2 in Supplementary Information). This renders likely the universal value of the findings irrespective microbiology. Since P. aeruginosa was a common VAP pathogen, we decided to continue animal experiments studying this species.
The ratio of BAL to serum albumin was increased after bacterial challenge (Fig. 3A) indicating widespread lung exudation and inflammation. After 124 h, VEGF-A but not TNF-α and IL-1β in the BAL increased (Fig. 3  B-D) . The levels of circulating mediators remained low (Fig. 3E,F) . Kidney cultures were sterile at all times of sacrifice. Low levels of circulating cytokines and kidney sterility indicate that the studied model was a lung infection model per se.
As infection reached chronicity after 124 h, bacterial overgrowth in the lung decreased (Fig. 4A,B) ; colistin treatment ended in pathogen eradication. At the same time points, VEGF-A in the lung increased compared to both 24 and 48 h (Fig. 4C,D) . Similar increase was not shown for any other mediator (Fig. 4E-L) . VEGF-A of the right lung was further increased after effective colistin treatment (Fig. 4C) .
Mice pre-treated with bevacizumab had lower concentrations of VEGF-A in the lungs (Fig. 5A ), lower lung outgrowth (Fig. 5B ) but greater concentrations of TNF-α and MPO lung activity (Fig. 5C ,D) .
DISCUSSION
In the clinical setting of VAP, a more than 45% increase in circulating VEGF-A after the first 4 days of ventilation are associated with a greater chance of early VAP resolution. This predictor of VAP resolution is independent of disease severity. A similarly late increase of VEGF-A in both BAL and lung tissue was also observed in an experimental mouse model of chronic lung infection by P. aeruginosa. When the infection was eradicated after treatment with colistin, VEGF-A levels further increased supporting a role of VEGF-A in the healing process of the lung. Although a chronic P. aeruginosa lung infection is associated with IFNγ responses from T-lymphocytes, 12 the animal data in this study showed unchanged concentrations in lung tissue over time, indicating innate immunity as the site of IFNγ production.
The presence of mechanical ventilation may be considered a major limitation in the interpretation of our clinical findings, since lung damage from the ventilator can lead to systemic over-expression of VEGF-A. 13 However, our animal study showed that the increase in VEGF-A was independent from the application of mechanical ventilation. The lack of flow cytometry of neutrophils in mouse BAL and MPO lung activity analysis instead of lung histological analysis are recognized as limitations to the experimental animal model.
In a mouse model of acute lung injury induced by bacterial lipopolysaccharide, VEGF-A was given intraperitoneally. VEGF-A treatment led to attenuation of the lung inflammation and decrease of infiltration by neutrophils.
14 This is in alignment with the increase of TNF-α and of MPO activity shown in our animal study after blockade of VEGF-A with bevacizumab pre- Figure 2 Time to resolution of VAP in relation to the change of VEGF-A serum levels on day 5 from the baseline day 1. The solid line indicates the group of patients with more than 45% increase of VEGF-A from the baseline day 1 levels (n = 43). The dashed line indicates the group of patients with less than 45% increase of VEGF-A from the baseline day 1 levels (n = 39). The P value of statistical comparison between the two groups of patients is shown. Log-rank: 7.99; P = 0.005. VAP, ventilator-associated pneumonia; VEGF, vascular endothelial growth factor. treatment. In these animals, low bacterial overgrowth is probably explained by the effective phagocytosis from highly infiltrating neutrophils. The increase of inflammatory mediators has also been shown after intravitreal injection of bevacizumab in glaucoma. 15 Results from a rat model of emphysema support the role of VEGF-A in the repair process of the lung after chronic inflammation. Rats treated with purified mesenchymal cells showed increased gene expression and protein levels of VEGF-A in the lung tissue, along with a decrease in the production of pro-inflammatory cytokines and significant attenuation of histologic lung inflammation. 16 Although this upregulation of VEGF-A production in the lung appeared associated with the attenuation of lung damage and improved tissue healing, it may be harmful in patients with interstitial pneumonia. 17 .When lung sections of patients with nonspecific interstitial pneumonia with accelerated fibrosis were compared with sections derived from patients with usual interstitial pneumonia, an extensive degree of neovascularization was found, associated with excess expression of VEGF-A at the tissue level. 17 The present study shows that an early increase in circulating VEGF-A in patients with VAP is associated with a greater chance of a clinical resolution of VAP. The animal experiments in mice show that after bacterial infection, levels of VEGF-A rise in parallel with the resolution of inflammation. Further clinical and mechanistic studies are required to define the role of VEGF-A in the resolution of VAP. Figure S1 Study flow chart. Figure S2 More than 45% increase of VEGF-A as the best trade-off of sensitivity and specificity for the resolution of ventilator-associated pneumonia. Table S1 Baseline demographic characteristics of patients without resolved VAP and of patients with resolved VAP. Table S2 Rates of VAP resolution in relation to the increase of circulating VEGF-A on day 5 and to the type of isolate.
